Novartis is preparing to present the trial findings to regulatory bodies in 2025. Credit: Novartis AG. Novartis has reported positive topline outcomes from the Phase III STEER trial of an ...
APAC was followed by North America and then Europe for percentage of clinical trials in Parkinson’s disease. Credit: AtlasStudio / Shutterstock. The Asia-Pacific (APAC) region is leading in the ...
RAG-17 is tailored for the SOD1 gene suppression in individuals with ALS having pathogenic mutations. Credit: CC7/Shutterstock. Ractigen Therapeutics has dosed the first subject in the randomised ...
Despite hitting its primary endpoints, the Novo Nordisk REDEFINE 1 Phase III trial saw patients achieving a weight loss of 22.7% after 68 weeks on CariSema. Credit: Getty Images / Bloomberg Danish ...